Eton Pharmaceuticals (ETON) 주식 개요
제약 회사인 이튼 파마슈티컬스는 희귀 질환 치료제의 개발과 상용화에 주력하고 있습니다. 자세히 보기
ETON Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Eton Pharmaceuticals, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$43.20 |
| 52주 최고가 | US$43.76 |
| 52주 최저가 | US$13.78 |
| 베타 | 0.86 |
| 1개월 변동 | 33.00% |
| 3개월 변동 | 82.97% |
| 1년 변동 | 196.09% |
| 3년 변동 | 1,482.42% |
| 5년 변동 | 701.48% |
| IPO 이후 변동 | 591.20% |
최근 뉴스 및 업데이트
Seeking Alpha • 12h
Eton Pharmaceuticals: Here Is How I Handle My Position With The Stock Skyrocketing (Downgrade)
Summary Eton Pharmaceuticals is rated Hold, with a base-case fair value of $38.75, about 7% below current levels, and a slightly optimistic fair value of $53. ETON’s business model leverages acquisitions of ultra-rare disease drugs, expanding its portfolio to 16 products and targeting two acquisitions per year. My probability-adjusted peak sales estimates are $205M for existing products and $185M for the pipeline, with future acquisitions modeled at ~$69.5M by 2035. With the stock skyrocketing, I trimmed my stock position, and I rolled up my partially covered Put options, for a combined half position. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).
내러티브 업데이트 • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.
내러티브 업데이트 • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Recent updates
Seeking Alpha • 12h
Eton Pharmaceuticals: Here Is How I Handle My Position With The Stock Skyrocketing (Downgrade)
Summary Eton Pharmaceuticals is rated Hold, with a base-case fair value of $38.75, about 7% below current levels, and a slightly optimistic fair value of $53. ETON’s business model leverages acquisitions of ultra-rare disease drugs, expanding its portfolio to 16 products and targeting two acquisitions per year. My probability-adjusted peak sales estimates are $205M for existing products and $185M for the pipeline, with future acquisitions modeled at ~$69.5M by 2035. With the stock skyrocketing, I trimmed my stock position, and I rolled up my partially covered Put options, for a combined half position. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).내러티브 업데이트 • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.내러티브 업데이트 • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.내러티브 업데이트 • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.내러티브 업데이트 • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.내러티브 업데이트 • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.내러티브 업데이트 • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.내러티브 업데이트 • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.분석 기사 • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...분석 기사 • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...새로운 내러티브 • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.분석 기사 • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...분석 기사 • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...분석 기사 • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...분석 기사 • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...분석 기사 • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...분석 기사 • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...분석 기사 • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...분석 기사 • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Sep 13
Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Eton Pharmaceuticals (NASDAQ:ETON) on Tuesday said it had acquired an FDA-approved rare disease product, betaine anhydrous for oral solution. Betaine anhydrous is a chemical that occurs naturally in the body. It helps in the metabolism of a chemical called homocysteine and prevents the buildup of it in the blood. High levels of homocysteine can cause problems with metabolism. The company plans to integrate the product later this year and expects the acquisition to be accretive to 2023 earnings, ETON CEO Sean Brynjelsen said in a statement. ETON stock -4.3% at $2.21 in morning trading.Seeking Alpha • Aug 14
Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Today, we revisit fast evolving biopharma name Eton Pharmaceuticals for the first time since October of last year. Since then, the company has launched several key products and made a key divestiture. What is ahead for this intriguing small cap concern? An investment analysis follows in the paragraphs below. I predict future happiness for Americans, if they can prevent the government from wasting the labors of the people under the pretense of taking care of them. ― Thomas Jefferson It has been almost a year since our last piece on Eton Pharmaceuticals (ETON). The stock shot up soon after that article was posted but has been in pullback mode since. The company posted second quarter results earlier this week. Given that it seems a good to revisit this small cap name. An analysis follows below. Seeking Alpha Company Overview Eton Pharmaceuticals is a commercial-stage biopharmaceutical concern based in Illinois. The company is focused on improving the formula, delivery, and/or safety of approved drugs employing the 505((B))(2) regulatory pathway. The stock currently trades just below three bucks a shares and sports and approximate market capitalization of $75 million. The company is in the early stages of commercialization with several products and has several more than could potentially launch over the next year. May Company Presentation The company breaks down its focus to two main areas. There are royalty products. These are products that are handled by partners with established salesforces for which Eton will get paid milestone payouts as well as royalties on sales. There are Orphan Drug Products which Eton will sell under its own label and have the greatest potential to impact margins and earnings. The company has recently launched two drugs in that category. May Company Presentation The first of which is Carglumic Acid tablets. If the company eventually meets its market share goals, this could be roughly a $15 million product annually. May Company Presentation Alkindi Sprinkle as described above is a much bigger potential opportunity and leadership believes this product could eventually do $100 million in annual sales. The product is 'co-promoted' by Tolmar Pharmaceuticals through their 60 plus sales reps. The company had a Hospital Products division that was gearing up for several commercial launches. However, in late June, Eton sold the rights and interests in Biorphen, Rezipres and Cysteine Hydrochloride products in that division to a subsidiary of Dr. Reddy's Laboratories (RDY). This deal came with a $5 million upfront payment as well as potential additional payments of up to $45 million, based on the achievement of certain event-based and sales-based milestones. This allows Eton to focus solely on its rare disease product portfolio. Second Quarter Results The company posted second quarter numbers on August 11th. Eton had a GAAP loss for the quarter of six cents a share. The consensus was projecting a slight profit for the quarter. Revenues did rise over 140% on a year-over-year basis to $7.4 million, which was slightly below expectations. It should be noted most of revenues was for milestone payments including the $5 million payment netted for the disposal of the assets in its Hospital Product division. Carglumic Acid sales saw 100% sequential growth and Alkindi Sprinkle sales were up 34% from the first quarter of this year, but both are coming off very low numbers as they are at the beginning of commercial launch phase. Zonisade was approved in July and will be marketed by Azurity Pharmaceuticals. During the quarter, Eton made good progress addressing FDA concerns about its marketing application for dehydrated alcohol injection. The company expects to resubmit the application for the product later this year. Approval and launch should occur in 2023. With approval, Eton would one of only 2 suppliers in this approximate $80 million annual market due to the orphan drug exclusivity protections. Management also continue to progress the development of its ZENEO® hydrocortisone autoinjector. A marketing application for this product should be filed with the FDA in 2023. Analyst Commentary & Balance Sheet The company ended the second quarter with $17 million in cash and marketable securities on the balance sheet after posting a net loss of $1.6 million in the second quarter. The company also is entitled to receive an additional $5 million milestone payment upon the launch of the recently approved Zonisade™ product. Approximately five percent of the outstanding float in Eton Pharmaceuticals is currently held short. There also has been no insider activity in the shares so far in 2022.주주 수익률
| ETON | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 15.2% | 1.9% | -0.7% |
| 1Y | 196.1% | 43.2% | 17.3% |
수익률 대 산업: ETON은 지난 1년 동안 43.2%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ETON은 지난 1년 동안 17.3%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| ETON volatility | |
|---|---|
| ETON Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: ETON는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ETON의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2017 | 44 | Sean Brynjelsen | www.etonpharma.com |
제약 회사인 이튼 파마슈티컬스는 희귀 질환 치료제의 개발 및 상용화에 주력하고 있습니다. 상용화된 희귀질환 제품으로는 중증 원발성 igf-1 결핍증 치료제인 인클렉스, 부신 기능 부전 치료제 알킨디 스프링클, 부신피질 기능 부전 치료제 킨디비, 윌슨병 치료제 갈진, 페닐케톤뇨증 치료제 PKU 골라이크, N-아세틸글루타메이트 합성효소 결핍증 치료제 카글루믹산, 호모시스틴뇨증 치료제 베타인 무수물, 티로신혈증 1형 치료제 니티시논 등이 있습니다. 또한 요붕증 치료제 ET-600, 신생아 당뇨병 치료제 암글리디아, 윌슨병 치료제 ET-700, 부신 기능 부전 치료제 ET-800, 부신 위기 치료제 제네오 하이드로코르티손 자동 주사기 등 개발 후기 단계에 있는 다양한 제품 후보를 개발 중입니다.
Eton Pharmaceuticals, Inc. 기초 지표 요약
| ETON 기초 통계 | |
|---|---|
| 시가총액 | US$1.13b |
| 순이익 (TTM) | -US$1.47m |
| 매출 (TTM) | US$86.93m |
13.6x
주가매출비율(P/S)-802.3x
주가수익비율(P/E)ETON는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ETON 손익계산서 (TTM) | |
|---|---|
| 매출 | US$86.93m |
| 매출원가 | US$35.02m |
| 총이익 | US$51.92m |
| 기타 비용 | US$53.39m |
| 순이익 | -US$1.47m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.054 |
| 총이익률 | 59.72% |
| 순이익률 | -1.70% |
| 부채/자본 비율 | 100.4% |
ETON의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/21 18:58 |
| 종가 | 2026/07/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Eton Pharmaceuticals, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Gary Nachman | Canaccord Genuity |